Figure 4: TDO deficiency does not change CNS infiltration and glial activation. | Scientific Reports

Figure 4: TDO deficiency does not change CNS infiltration and glial activation.

From: Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis

Figure 4

Immunohistochemistry images of spinal cord slides from WT and TDO−/− EAE mice sacrificed at the peak of disease. (a) representative HE stainings, (b) infiltrative lesion load per slide, (c) representative CD3 stainings, (d) % CD3+ stained area per slide, (e) representative Mac3 stainings, (f) % Mac3+ stained area per slide, (g) representative GFAP stainings, (h) GFAP+ cell count per defined area of the slide, (i) representatitve Iba1 stainings, (j) Iba1+ cell count per defined area of the slide. Mice were sacrificed on day 14 after immunization. At least 3 spinal cord slices of each mouse were analyzed with 6 mice per group. Statistical analysis was achieved by blinded investigators: (b) manual count of infiltrative lesions per slide, (h,j) manual count of single cells per designated area, (d,f) computational analysis of stained area per slide using FIJI/ImageJ software. Means ± SEM are shown. No statistically significant differences could be detected according to unpaired Student’s t-tests. Scale bars: 200 μm.

Back to article page